Abstract: An opposed substrate (9?) comprises: a substrate (1); a static electricity protective electrode (2), a bridging electrode (4) and a touch induction electrode (6) comprising a plurality of sub-units sequentially formed on the substrate (1), wherein the distribution of the static electricity protective electrode (2) on the substrate (1) corresponds to dummy regions between sub-units, and the static electricity protective electrode (2), the bridging electrode (4) and the touch induction electrode (6) are insulated from each other. The opposed substrate (9?) has a good touching effect. A method for manufacturing the opposed substrate, and a liquid crystal display touch panel are also disclosed.

Abstract: It discloses a pixel circuit and a driving method thereof. The pixel circuit includes a light-emitting device (OLED), a driving transistor (DTFT), a storage capacitor (Cst), a first switching transistor (T1), a second switching transistor (T2), a compensating transistor (T3) and a fifth switching transistor (T5). The light-emitting device (OLED) has one terminal connected to a power supply (VDD). The driving transistor (DTFT) has a first electrode connected to another terminal of the light-emitting device (OLED), a second electrode connected to a first electrode of the fifth switching transistor (T5), and a gate connected to a first electrode of the first switching transistor (T1). The first switching transistor (T1) has a second electrode connected to a data line, a gate connected to a scan line, and a first electrode connected to the gate of the driving transistor (DTFT).

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: The present invention discloses array substrate, display device and method for controlling refresh rate of an array substrate. The array substrate includes; a plurality of pixel structures each including gate line, data line, common electrode line, first switching element at intersection of the gate line and the data line, pixel electrode, second switching element, and first transparent electrode. Gate, source and drain of the first switching element are connected to the gate line, the date line and the pixel electrode, respectively. Gate, source and drain of the second switching element are connected to second switching controlling line, common electrode signal terminal and the first transparent electrode, respectively. A first storage capacitance is formed between the pixel electrode and the common electrode line and/or between the pixel electrode and the gate line, and a second storage capacitance is formed between the pixel electrode and the first transparent electrode.

Abstract: It discloses a pixel circuit and a driving method thereof. The pixel circuit includes a light-emitting device (OLED), a driving transistor (DTFT), a storage capacitor (Cst), a first switching transistor (T1), a second switching transistor (T2), a compensating transistor (T3) and a fifth switching transistor (T5). The light-emitting device (OLED) has one terminal connected to a power supply (VDD). The driving transistor (DTFT) has a first electrode connected to another terminal of the light-emitting device (OLED), a second electrode connected to a first electrode of the fifth switching transistor (T5), and a gate connected to a first electrode of the first switching transistor (T1). The first switching transistor (T1) has a second electrode connected to a data line, a gate connected to a scan line, and a first electrode connected to the gate of the driving transistor (DTFT).

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: The present invention relates to a newly discovered 44 kD isoform of Pim-1 kinase made in human cells, and to the gene and messenger RNA for the 44 kilodalton isoform. The invention further describes methods and compounds for treating, especially prostate and hematopoietic cancer, by inhibiting expression of the 44 kD isoform of Pim-1 kinase, or its ability to phosphorylate Etk kinase and breast cancer resistance protein (BCRP).